Clinical Trials
19 trialsNCT07087860 2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04848519 2026-02-19
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Phase 2 Active not recruiting
NCT07125547 2025-08-15
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06983210 2025-08-14
GRAPE
Nagoya University
Phase 2 Recruiting
NCT05756569 2025-07-28
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
Phase 2 Recruiting
NCT02122172 2025-04-25
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Phase 2 Terminated
NCT04398368 2023-08-08
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
Mayo Clinic
Phase 2 Terminated
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT02612194 2022-11-03
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT03179943 2021-11-04
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT00749892 2020-09-10
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT02438865 2018-09-13
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
Mansoura University
Phase 2 Completed
NCT01639521 2014-01-29
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Phase 2 Withdrawn
NCT01426126 2011-12-07
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Asan Medical Center
Phase 2 Completed